RT Journal Article SR Electronic T1 Long term treatment outcome in multi drug resistant tuberculosis JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP P3324 VO 40 IS Suppl 56 A1 Rajendra Prasad A1 Abhijeet Singh A1 Sanjay Verma A1 Ramawadh singh Kushwaha A1 Rajiv Garg A1 Sanjeev Kumar Verma A1 Rahul Srivastava A1 Amita Jain YR 2012 UL http://erj.ersjournals.com/content/40/Suppl_56/P3324.abstract AB Background: Multi Drug Resistant tuberculosis (MDR-TB) is an increasing worldwide problem which is difficult to treat and has greater risk of relapse.Aims and Objective: To analyze long term treatment outcome with second line drugs in patients with MDR-TB.Methods: A descriptive analyses of 93 consecutive patients with MDR-TB attending the Dept of Pulmonary Medicine, CSMMU, between June 1998 to February 2008 with follow-up till December 2010. All patients were admitted for average duration of 70 days and received a regimen chosen from Kanamycin, PAS, Ethionamide, Cycloserine, Flouroquinolone, Isoniazid, Ethambutol and Pyrazinamide. Patients outcome was considered as cure when atleast two of the last three (At 12, 18 & 24 m) cultures were negative and as failure when the same were positive.Results: All the patients had resistance to at least Isoniazid and Rifampicin with mean no. of 3.38 drugs. Average duration of pretreatment chemotherapy was 34.5 (10-62) months. Out of 93 patients enrolled, 75 completed the treatment as planned, 5 patients died during treatment, and 13 patients abandoned it or lost to follow up. Considering the best scenario cure rate was 93.33% (70/75) and in worst scenario cure rate was 75.27 % (70/93). Out of 75 cured, 68 came for follow-up for mean duration of 53.3 (10-98) months.Relapse rate was 9.33%(7/75). Significant side effects were experienced in 13 (13.98%) patients.Conclusions: In MDR-TB patients, regimen consisting of Ethionamide, PAS, fluoroquinolone and Cycloserine with injection Kanamycin in initial 4-8 months appears to be safe and effective. MDR TB can be cured successfully with appropriate combination chemotherapy for an adequate duration requiring a strategic approach.